FOR HEALTHCARE PROFESSIONALS
-
56:48
ADVANCES IN ASSESSING & TREATING SEVERE HYPOGLYCEMIA IN PRACTICE
**NO LONGER AVAILABLE FOR CREDIT**
Severe Hypoglycemia is Still a Serious & Significant Problem in Both Type 1 & Type 2 Diabetes
Severe Hypoglycemia is still a serious and significant problem in persons with type 1 and type 2 diabetes treated with sulfonylureas and/or insulin. Providers can help to identify, prevent and address this problem by assessing patients at risk. Avoidance is the first step and being prepared with the best rescue therapies is essential for rapid recovery. We’re taking a deep dive into what you need to know to address hypos in your patients with diabetes.0Mar 06, 2023 -
08:49
CGM: Not Just For Type 1 Diabetes
Continuous Glucose Monitors (CGMs) have been a game changer for the type 1 diabetes community, becoming the standard of care for T1D. But all of these benefits can (and should) be applied to type 2 diabetes as well! Learn more at provider.dexcom.com140Nov 09, 2022 -
01:13:32
2022 Diabetes Forum: Examining the Biggest Breakthroughs in Diabetes Care
TCOYD and The diaTribe Foundation’s 3rd Virtual Diabetes Forum took place July 13th, 2022, and featured an impactful and sophisticated discussion on the cutting-edge developments in diabetes from key opinion leaders. These world-renown experts shared insights on the current state of diabetes care, and discussed ground-breaking research from the 2022 ADA Scientific Sessions.
Moderators: TCOYD’s Dr. Steven Edelman & diaTribe’s Kelly Close
Panelists:
Leslie Eiland, MD (Omaha)
James Gavin, MD (Fayetteville)
Jeremy Pettus, MD (San Diego)
William Polonsky, PhD, CDCES (San Diego)
Carolyn Wysham, MD (Spokane)
Topics Included:
• What we now know about COVID-19 and diabetes
• Updates on the ADA Standards of Care
• New data on cardiovascular and renal protection outcome studies: SGLT2 inhibitors and GLP1-RAs
• The changing landscape for the treatment of obesity
• The latest in hybrid closed loop systems including Tandem CIQ, Omnipod 5, Looping, and Medtronic 780G
• CGM updates including the Eversense 180 day, Dexcom G7 and FreeStyle Libre 3
• Updates on dual- and triple- agonists in development
• Smart pens and their impact on diabetes care
• Adjunctive therapies for T1D
• Next steps on multiple cures for T1D, particularly cell-based therapy
• Telehealth and its impact
• What will truly affect social determinants of health and health equity
• “Remission” for T2D600Aug 09, 2022 -
01:27:14
TCOYD Deep Dive: Poor Glycemic Control
29Nov 24, 2021 -
01:29:12
TCOYD Deep Dive: CGMs, Pumps, and Hybrid Closed Loop Systems
69Sep 30, 2021 -
01:28:30
MAKING THE CONNECTION DEEP DIVE: Clinical Application of Telehealth for Diabetes Patients
***NO LONGER AVAILABLE FOR CREDIT****
Telehealth has become an effective, efficient, and safe way to see diabetes patients during COVID, however it is here to stay for the long-term. We’ve assembled a group of expert faculty who have mastered the art of video visits and will take a deep dive into different telehealth methods you can implement to keep up with your patients even in the post-COVID period.23Sep 09, 2021 -
01:28:10
MAKING THE CONNECTION DEEP DIVE: Prevention, Early Detection & Aggressive Management of CAD and CKD
***NO LONGER AVAILABLE FOR CREDIT****
Coronary artery and chronic kidney disease are serious complications of diabetes that often lead to morbidity and mortality, as well as take a toll on the entire family. Making a significant impact involves not only prevention and early detection, but also aggressive management of both heart and kidney disease. In addition to discussing the basics of treating heart and kidney disease, we will do a deep dive into the cardiorenal effects of SGLT2 inhibitors and GLP1RAs to help you help your patients prevent, detect, and manage coronary artery and chronic kidney disease.344Aug 06, 2021 -
01:52:12
15th Annual Diabetes Forum: Exploring the Brightest Discoveries in Diabetes
Our 2021 Diabetes Forum, hosted by TCOYD and diaTribe, featured candid discussions on the following topics:
• The hottest trials and data revealed at this year’s ADA Symposium
• The latest ADA Standards of Care and CVOT/DKD treatment algorithm updates
• Recent updates on the SGLT2 inhibitors: CHF and renal protection
• High dose GLP1-RAs, dual and triple agonists in development
• Advances in drug delivery systems
• The latest in CGM, pumps, hybrid closed looped and fully closed AP systems
• TIR and other analytics that have and will become important
• Advances in pramlintide formulations, glucagon, including glucagon receptor antagonists
• Cure-based immune therapies for T1D
• Telehealth/digital diabetes care apps
Moderators: Steve Edelman, MD and Kelly Close, Founder of the diaTribe Foundation
Panelists: Jeremy Pettus, MD, Daniel Drucker, MD, Professor Rury Holman, FRCP, FMedSci , Sam Dagogo-Jack, MD, DSC, Davida Kruger, MSN, APN-BC, BC-ADM
A list of the Q&A can be found here: https://bit.ly/3wqkVzs408Jul 06, 2021